According to a 2020 study, it costs $1.5bn to develop a new medicine, with only 12% of new drug candidates making it to the clinical phase will secure FDA approval. Coupled with unprecedented pressure from the pandemic in 2020, disrupted clinical supplies, rapid shift of pipeline focus, challenges of accessing new vendors and managing financial milestones for clinical trials have led to Procurement, Sourcing and Clinical Finance leaders to rethink their strategies.

With such notable shifts in supply-market dynamics, the 5th R&D Sourcing & Procurement Summit returns in 2021 to unite 100+ leading biopharma, contract research / manufacturing organizations as well as key industry solution providers, to share and discuss revised best operating practices following a year of changing tactics and resource reprioritization.

As long-term impacts become apparent from 2020, be part of this growing community where you can share and learn alongside the likes of Pfizer, Charles River, BMS & Takeda, on proactively anticipating radical changes, de-risking sourcing and vendor tactics and integrating latest innovative tech reaching the market – all to accelerate novel R&D in a time and cost-effective manner.